Stocksrunner Posted - 5 days ago

After Hours Technical Alert! Multiple heavyweights $GD $WST $APPF $HALO $TRI breaking below crucial 200-day MAs today! Watch these levels closely next week - could signal bigger moves ahead. Oversold bounces or further breakdowns? https://stocksrunner.com/posts/1384

Addictz1983 Posted - 1 week ago

$HEXO $WST $SPY Ready for your next runner? Add $ELAB. It’s taking off! Get in now!!!

Addictz1983 Posted - 1 week ago

$WST $ALB just fyi.. ELAB is taking off right now. Add it to your watch list. Thanks. $COMS $AMTM

Stocksrunner Posted - 2 weeks ago

🔥 Trending Now: $ALB $WST $WEC $RGA $VSAT are heating up with rising (and falling) short interest! From Albemarle’s lithium buzz to ViaSat’s Starlink drama, these stocks are stirring the pot. Are they opportunity or risk? https://stocksrunner.com/posts/1334

insiderbuyingselling Posted - 10/31/24

$WST new insider selling: 703 shares. http://insiderbuyingselling.com/?t=WST

IN0V8 Posted - 10/29/24

$WST Jefferies raises target price to $393 from $345

DividendPower Posted - 10/25/24

Recent Dividend Increases - Updated 10/25/24 https://www.dividendpower.org/dividend-increases/ $ROL $AB $WST $CHDN $PNW

FilingFact Posted - 10/25/24

New financial insights available on https://www.filingfact.com/ from yesterdays report of $WST With the launch of the new platform we are offering 1 month of FREE Premium Access (worth $49) to the first 100 users! 🥳 💬 We’d love to hear your thoughts—your feedback will help us improving our service to your needs! For any questions, ideas, or support, reach out to us at [email protected] 👉 Join today and be a part of the journey!

swingingtech Posted - 10/24/24

$MOH $WST $TSLA $POOL https://wallstreetwaves.com/thursday-market-highlights-top-performers-in-healthcare-and-consumer-goods/

thetechtrader Posted - 10/24/24

$WST surged to 328 +42, spiked, tagged 340 +53. Extension targets are 325 & 330-32+ Support near 307 & 304. #technicaltrading #daytrade #tradealert #marketrecap #stockstowatch #stockstobuy

whiskeykid Posted - 10/24/24

$WST this bad boy finally heading up?

kiwitc2000 Posted - 10/24/24

$QS $MOH $WST The theme today seems to be big pop on earnings coming out of a long downtrend. If this theme holds this earnings cycle I'm setting up a new filter LOL!

kiwitc2000 Posted - 10/24/24

$WST Big winner on earnings coming out of nowhere. Holding, in case this continues tomorrow.

IN0V8 Posted - 10/24/24

$WST is up more than +17% after reporting Q3 net sales of $746.9 million, stronger than the consensus of $709.7 million, and raising its full-year net sales forecast to $2.88 billion-$2.91 billion from a previous forecast of $2.87 billion-$2.90 billion, above the consensus of $2.87 billion.

AskLou Posted - 10/24/24

$WST talk about a trend with no friends, lol. @coloradoriley

thetechtrader Posted - 10/24/24

$WST formed a strong base and broke out! Extension targets are 325 & 330-32+ Support near 307 & 304. #technicaltrading #daytrade #tradealert #marketrecap #stockstowatch #stockstobuy

DonCorleone77 Posted - 10/24/24

$WST West Pharmaceutical ups FY24 adjusted EPS view to $6.55-$6.75 from $6.35-$6.65 Consensus $6.51. Raises FY24 revenue view to $2.88B-$2.91B from $2.87B-$2.9B, consensus $2.87B. The company said, "As a result of favorable currency movements, the Company increased its full year 2024 net sales guidance range to $2.875 billion to $2.905 billion, compared to a prior range of $2.870 billion to $2.900 billion. Anticipating a decrease of approximately 1.5% to 2% for organic net sales. Net sales guidance includes an estimated full-year 2024 headwind of approximately $1.0 million based on current foreign currency exchange rates, compared to previous guidance of a headwind of approximately $5.0 million. Full-year 2024 adjusted-diluted EPS is expected to be in a range of $6.55 to $6.75, compared to prior guidance range of $6.35 to $6.65. Our updated adjusted-diluted EPS guidance incorporates a foreign currency exchange rate headwind of $0.02, compared to prior guidance which anticipated a foreign currency exchange rate headwind of $0.03. The updated guidance also includes EPS of $0.26 associated with first nine-months 2024 tax benefits from stock-based compensation. For the fourth-quarter 2024, our EPS guidance range assumes a tax rate of 22% and does not include potential additional tax benefits from stock-based compensation. Any tax benefits associated with stock-based compensation beyond those recorded in the first nine-months of 2024 would provide a positive adjustment to our full-year adjusted-diluted EPS guidance. Full-year 2024 capital spending guidance is unchanged and is expected to be $375 million."

DonCorleone77 Posted - 10/24/24

$WST West Pharmaceutical reports Q3 adjusted EPS $1.85, consensus $1.50 Reports Q3 revenue $746.9M, consensus $709.62M. Eric M. Green, president, CEO and chair of the board commented; "We are pleased to report solid third quarter results. Our West team across the globe continues to execute at a high-level, motivated by our purpose of improving patient lives. A key aspect of our strategy is West's team of scientific thought leaders and technical experts who continue to drive strong partnership and close collaboration with our customers. This reinforces my confidence in West's execution capabilities, as we continue to deliver our proven market-led strategy and attractive long-term potential."

WeeklyTrader Posted - 1 month ago

Headwinds are strong for $WST! RSI: 45.97% 50-day MA: $300.17 200-day MA: $340.67

Clargy Posted - 1 month ago

$WST Saved by the wick

Nosh Posted - 1 month ago

$WST Almost at a buy level...

NVDAMillionaire Posted - 07/29/24

$WST West Pharmaceutical Services, Inc. (WST): A Comprehensive Analysis of a Leading Innovator in Injectable Drug Delivery http://beyondspx.com/2024/07/29/west-pharmaceutical-services-inc-wst-a-comprehensive-analysis-of-a-leading-innovator-in-injectable-drug-delivery/

GPS_hawkeye Posted - 07/26/24

$EW new 52-week lows in healthcare $EW $WST $IPA $RNVA $FOXO -- 52week and all-time low; millions in debt ; near zero revenues for a few years; you borrow money to make money, right? hasn't happened at FOXO

briefingcom Posted - 07/25/24

Gapping down: $MXL -26.4% $EW -24.1% $WST -14.7% $F -12.8% $STM -12.7%

mTOR Posted - 07/25/24

$WST wow that's bad!

DonCorleone77 Posted - 07/25/24

$WST West Pharmaceutical cuts FY24 adjusted EPS view to $6.35-$6.65 from $7.63-$7.88 Consensus $7.74. Cuts FY24 revenue view to $2.87B-$2.9B from $3B-$3.03B, consensus $3.01B. The company said, "The Company is updating full-year 2024 net sales guidance to a range of $2.870 billion to $2.900 billion, compared to a prior range of $3.000 billion to $3.025 billion. Organic net sales are now expected decrease approximately 1% to 2%. Net sales guidance includes an estimated full-year 2024 headwind of approximately $5.0 million based on current foreign currency exchange rates, compared to prior guidance of approximately $8.0 million. Full-year 2024 adjusted-diluted EPS is expected to be in a range of $6.35 to $6.65, compared to prior guidance range of $7.63 to $7.88. Full-year adjusted-diluted EPS guidance range includes an estimated headwind of approximately $0.03 based on current foreign currency exchange rates, compared to prior guidance of $0.04. The updated guidance also includes EPS of $0.22 associated with first-half 2024 tax benefits from stock-based compensation. For the second half of the year, our EPS guidance range assumes a tax rate of 22% and does not include potential tax benefits from stock-based compensation. Any tax benefits associated with stock-based compensation beyond those recorded in the first-half 2024 would provide a positive adjustment to our full-year adjusted-diluted EPS guidance. Full-year 2024 capital spending is expected to be $375 million, an increase from the previous estimate of $350 million."

DonCorleone77 Posted - 07/25/24

$WST West Pharmaceutical reports Q2 adjusted EPS $1.52, consensus $1.74 Reports Q2 revenue $702.1M, consensus $729.35M. "The second quarter continued to be impacted by an elevated level of customer destocking," said Eric Green, President, Chief Executive Officer and Chair of the Board. "While the results were below our expectations, we were encouraged to see our second-quarter revenues increase sequentially. Our outlook anticipates that revenues in the second half of the year will be stronger than the first half. Based on our confirmed order book and ongoing customer conversations, we remain confident in a return to organic growth in the fourth quarter and as we move into 2025. We see considerable growth opportunity in the markets we serve, and our investments position us to create continued value for our customers, patients and shareholders well into the future."

epsguid Posted - 07/25/24

$WST reported earnings of $1.52, consensus was $1.77 via @eWhispers #epsmiss http://eps.sh/d/wst